← Back to Search

Radioactive Agent

yttrium Y 90 glass microspheres for Liver Cancer

Phase < 1
Waitlist Available
Led By Rikabi Ali, M.D.
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial uses radiolabeled glass beads to treat patients with unresectable hepatocellular carcinoma (liver cancer). The beads release radiation to kill the cancer cells.

Eligible Conditions
  • Liver Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse experiences
Response to treatment
Survival time

Side effects data

From 2016 Phase 2 trial • 45 Patients • NCT00956930
88%
Fatigue
29%
Nausea
25%
Anorexia
25%
Abdominal Pain
25%
Bilirubinemia
25%
Alkaline Phosphatase toxicity
21%
Aspartate aminotransferase toxicity
13%
Alanine aminotransferase toxicity
13%
Liver Decompensation
8%
Sepsis
8%
Hyperbilirubinemia
4%
Fever
4%
leukopenia
4%
Constipation
4%
Hypoalbuminemia
4%
Leukopenia
4%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I (Radioembolization)
Arm II (Transarterial Chemoembolization [TACE])

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (yttrium Y 90 glass microspheres)Experimental Treatment3 Interventions
Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TheraSphere
2007
Completed Early Phase 1
~2150
yttrium Y 90 glass microspheres
2010
Completed Phase 2
~360

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
289,877 Total Patients Enrolled
Rikabi Ali, M.D.Principal InvestigatorOhio State University Comprehensive Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
Ali Rikabi 2010. "Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02072356.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top